![Contribution of big pharma to the industry innovation decreased over time Annual new drug approvals [%] Pharma implications Source: Johnston Blakely & Company biotechnology report 2009 59 1997 43 58 1998 51 49 1999 58 42 2000 39 61 2001 2006 41 48 52 2002 74 2005 71 29 2003 33 67 84 16 2004 26 100% ,[object Object],[object Object],[object Object],39 21 45 41 31 33 38 43 40 49 # of drug approvals Bio / specialty pharma Large pharma](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recomendados
Recomendados
Mais conteúdo relacionado
Mais procurados
Mais procurados (20)
Destaque
Destaque (17)
Semelhante a 1 3 Innovation Kirschbaum
Semelhante a 1 3 Innovation Kirschbaum (20)
Mais de Silja Chouquet
Mais de Silja Chouquet (17)
1 3 Innovation Kirschbaum
- 1. How mid-sized players can out-innovate big pharma Bernd Kirschbaum at INSEAD Healthcare Alumni Summit, October 8, 2009
- 4. 1. Aggressive R&D productivity goals + high risk projects 2. Not enough resources managing too many projects plus “cutting corners” 3. Quality of projects decline cycle times increase 4. Increasing attrition rates 5. More projects required to meet same goals Large companies have tried to play an unsustainable numbers game Ensure effective portfolio management but use relevant Key Performance Parameters . . . . “ The Vicious Cycle“
- 5. Stay close to science Avoid misjudgment of technologies based on wishful thinking and/or despair Genomics Era Post-Genomics Era
- 7. Constant optimization of a global innovation network Effective use of external scientific and biotech network is essential
- 9. Stratified Medicine and Pharma Business – An opportunity for mid-size players Improved benefit / risk ratio Opens doors to new indications Higher & faster market penetration Better price and reimbursement Faster, more directed development Smaller target market Higher R&D costs per applicant Complication through Dx testing in practice Business Outcome + -